Hematologic Malignancies

HEMATOLOGIC MALIGNANCIES

Hematologic malignancies are neoplastic cancers that interfere with the production and function of blood cells in blood, bone marrow and lymph nodes. They include leukemias, lymphomas, myelomas, and are characterized by a wide spectrum of genetic and gene expression alterations.

Our genomic tests for different hematologic malignancies provide critical information for clinical diagnosis, subtype classification, risk stratification, drug resistance mechanisms and treatment decision-making. They also serve to monitor minimum residual disease, detect disease recurrence/resistance, and identify patients with the risk of disease recurrence after bone marrow transplantation by evaluating transplantation tolerance through hematopoietic chimerism.

HEMASALUS™

Comprehensive genomic profiling for all hematologic malignancies 

Hemasalus™ analyses mutations and selected translocations of 475 key genes in hematologic malignancies by targeted DNA-sequencing (Hemasalus™ D), or in combination with whole transcriptome mRNA-sequencing (Hemasalus™ DR) to detect a broader range of gene translocations and expression changes.

WHO IS IT FOR

Patients with hematologic malignancies

SAMPLE TYPES FOR LYMPHOMAS
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and cerebrospinal fluid)

Peripheral blood or bone marrow  

SAMPLE TYPES FOR LEUKEMIAS AND MYELOMAS

Peripheral blood or bone marrow  

LYMPH™

Comprehensive genomic profiling for B Cell and T Cell lymphoma 

Lymph™ analyses mutations and selected translocations in 121 key genes in B cell lymphoma and 102 key genes in T cell lymphoma by targeted DNA-sequencing (LymphB/T D), or in combination with whole transcriptome mRNA-sequencing (Lymph™B/T DR) to detect a broader range of gene translocations and expression changes.

WHO IS IT FOR

LYMPH™ B D/DR

Patients with B cell lymphoma 

LYMPH™ T D/DR

Patients with

  • T lymphoblastic lymphoma (TLL)
  • Angioimmunoblastic T cell lymphoma (AITL)
  • Extranodal NK/T cell lymphoma (nasal type) (ENKTCL-NT)
  • Peripheral T-cell lymphoma (not otherwise specified) (PTCL-NOS)
  • Anaplastic large cell lymphoma (ALCL) 

 

SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and cerebrospinal fluid)

Peripheral blood or bone marrow  

LEUMYE™

Comprehensive genomic profiling for myeloid neoplasm

Leumye™ analyses mutations and selected translocations in 88 key genes in myeloid neoplasm by targeted DNA-sequencing (Leumye D), or in combination with whole transcriptome mRNA-sequencing (Leumye DR) to detect a broader range of gene translocations and expression changes.

WHO IS IT FOR

All patients with myeloid neoplasm

  • Acute myeloid leukemia (AML) and related neoplasms
  • Myelodysplastic syndromes (MDS)
  • Myeloproliferative neoplasms (MPN)
  • MDS/MPN
SAMPLE TYPES

Peripheral blood or bone marrow  

ALLEUDR™

Comprehensive genetic profiling for acute lymphoblastic leukemia (ALL) 

ALLeuDR™  analyses mutations and selected translocations of 66 key genes in ALL by targeted DNA-sequencing in combination with whole transcriptome mRNA-sequencing to detect various ALL-related gene fusions, including all BCR-ABL1 fusions and common fusions in Ph-like ALL. This process assists with disease diagnosis and classification. It also assesses genetic predisposition to hereditary leukemia.

WHO IS IT FOR

Patients with ALL

SAMPLE TYPES

Peripheral blood or bone marrow  

HEMARNA™

Targets 232 fusion genes in hemolymphatic tumors

Hematolymphoid tumors are a group of highly heterogeneous diseases. So far, more than 100 fusion genes have been in corporate into WHO’s classification of hematolymphoid tumors. Fusion gene testing is crucial in diagnosis, treatment decision making, MRD monitoring and prognosis.

WHO IS IT FOR
  • Patients with hematolymphoid tumors (including acute lymphoblastic lymphoma, acute myeloid leukaemia, myeloproliferative neoplasms, lymphomas and lymphomas)
  • Patients with hematolymphoid tumors but are ‘pan-negative’ or possess non-classical fusions and require further fusion testing
  • Patients with specific fusion mutations undergoing dynamic monitoring after treatment or relapse
SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and cerebrospinal fluid)

Peripheral blood or bone marrow  

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us